Research Pipeline

Compound Primary Indications Target
Pre-Clinical Phase 1 Phase 2 a Phase 2 b Phase 3 Approval
GRC 17536 Neuropathic Pain TRPA1 Inhibitor
+
New Chemical Entity
(NCE)
GRC 27864 Relief from Osteoarthritic pain mPGES-1 Inhibitor
+
New Chemical Entity
(NCE)
Vatelizumab (GBR 500) Multiple Sclerosis VLA – 2 Antagonist (mAb)
+
Novel Biological Entity
(NBE)
GBR 830 Autoimmune disease OX40 Antagonist (mAb)
+
Novel Biological Entity
(NBE)
GBR 900 Inflammatory pain TrkA Antagonist
+
Novel Biological Entity
(NBE)
GBR 1302 HER2 positive cancers such as breast Cancer, gastric cancer & ovarian Cancer HER2xCD3 (bispecific mAb)
+
Novel Biological Entity
(NBE)
GBR 1342 Multiple myeloma CD38xCD3 (bispecific mAb)
+
Novel Biological Entity
(NBE)

About Us

Leading, integrated, global, research-led organization. Words which define us and our vision to discover a healthier future
Know More